Drug Trial Radar · NCT06525350
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jul 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
256
Planned (sponsor's estimate)
Start
Jul 2024
Primary completion
Dec 25, 2026
Study completion Jun 25, 2028
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (randomized controlled study). The main purpose of Stage 1 is to preliminarily evaluate the safety and tolerability of the combination of glumetinib Tablets and Docetaxel for Injection(Albumin Bound)(HB1801) in the treatment of MET-overexpressed non-small cell lung cancer (NSCLC); The main purpose of Stage 2 is to evaluate the efficacy of the combination of glumetinib tablets and HB1801 compared to glumetinib tablets monotherapy or docetaxel in the treatment of MET-expressed NSCLC.
Conditions
- Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
Interventions
Glumetinib tabletsDrug
An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
HB1801 (docetaxel, albumin-bound)Drug
An improved new formulations of docetaxel
DocetaxelDrug
A chemotherapy drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT) occurrence and incidenceTime frame: Up to approximately 48 months after the first participant is enrolled
- Recommended phase 2 dose(RP2D) of the combination therapyTime frame: Up to approximately 48 months after the first participant is enrolled
- Adverse events (AE) and serious adverse events (SAE) occurrence and incidenceTime frame: Up to approximately 48 months after the first participant is enrolled
- Objective response rate (ORR) per RECIST 1.1Time frame: Up to approximately 48 months after the first participant is enrolled
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.